 |
| Biosensors improve drug targeting with imaging capabilities.--Courtesy of the Garvan Institute |
Researchers in the U.S., the U.K. and Australia have developed a biosensor nanotechnology that could improve drug delivery for the treatment of pancreatic cancer while allowing for imaging at the same time, according to a release from the Garvan Institute in Australia. The biosensors deliver Bristol-Myers Squibb's ($BMY) Phase II antitumor drug dasatinib while also showing how cancers spread and how they respond to the drug in real time via three-dimensional visualization. The nanoparticles, as shown in a study published in the journal Cancer Research, could also be used in combination therapies to break down tissue around a tumor for better drug delivery. Release | Study (PDF)